Patients Return on Engagement (ROE): A new framework to better captur... Return on Engagement (ROE) is a call to action to better capture the multifaceted value of patient engagement.
Patients Exploring mixed episodes in bipolar I disorder: When mania a... One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Patients Reframing obesity beyond stigma and simplicity Deep Dive editor Eloise McLennan reports on Novo Nordisk's inaugural Weight Talks Summit in London.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Patients World Bipolar Day: Recognising bipolar I disorder and addres... BD-I is a brain-based condition that affects mood and energy regulation to an extent that disrupts daily life.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
